RESEARCH ARTICLE

Neoadjuvant radiotherapy for locoregional Siewert type II gastroesophageal junction adenocarcinoma: A propensity scores matching analysis

Yuan Zhou¹, MengXiang Tian¹, Cenap Güngör², Dan Wang¹,²*

¹ Department of General Surgery, Xiangya Hospital, Central South University, Changsha, China, ² Department of General Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

* wangdan19931006@outlook.com

Abstract

Objective

To analyze the effect of neoadjuvant radiotherapy (nRT) on prognosis in patients with locoregional Siewert type II gastroesophageal junction adenocarcinoma (GEA).

Method

All patients pathologically diagnosed as Siewert type II GEA between 2004 and 2015 were retrieved from the Surveillance, Epidemiology and Final Results (SEER) database. We analyzed the impact of different treatment regimens on the prognosis in each stage. Survival analysis was performed by Kaplan-Meier (K-M) method. Multivariate Cox model and propensity score matching was further used to verify the results.

Results

4,160 patients were included in this study. The efficacy of nRT was superior to that of adjuvant radiotherapy (aRT) (p = 0.048), which was the same as that of surgery combined with chemotherapy (p = 0.836), but inferior to the overall survival (OS) of surgical treatment alone (p < 0.001) in T1-2N0M0 patients. Patients receiving nRT had distinctly better survival than those receiving surgical treatment alone (p = 0.008), but had similar survival compared with patients treated with aRT (p = 0.989) or surgery combined with chemotherapy (p = 0.205) in the T3N0/T1-3N+M0 subgroup. The efficacy of nRT is clearly stronger than that of surgical therapy alone (p < 0.001), surgery combined with chemotherapy (p < 0.001), and aRT (p = 0.008) in patients with T4 stage. The survival analysis results were consistent before and after propensity score matching.

Conclusion

In these carefully selected patients, the present study made the following recommendations: nRT can improve the prognosis of patients with T3N0M0/T1-3N+M0 and T4 Siewert type II
Introduction

It was estimated that about 18,000 new cases and 13,000 deaths from esophageal cancer occur in the United States in 2020 [1]. Adenocarcinoma, accounting for 75% of esophagus cancers, is mainly located in the lower esophagus and gastroesophageal junction (GEJ) in the US, and its incidence has raised significantly since the 1970s [2]. Most patients with gastroesophageal junction adenocarcinoma (GEA) often have a terrible prognosis, with a 5-year survival of less than 25%, because of late-stage diagnosis and rapid spread [3]. Siewert classification is grounded on the anatomical distance between the tumor center and the GEJ, which divides GEA into three grouplets: Siewert type I, type II, and type III [4] and is now widely used in clinical practice. Siewert type I (distal esophageal adenocarcinoma) originates from the specialized intestinal area of the esophagus (such as Barrett’s esophagus), which can infiltrate the esophagus-gastric junction from above (located 1–5 cm above the GEJ); Siewert type II (cardia cancer) originates from the junction of the esophagus and stomach (located 1 cm above the GEJ to 2 cm below); Siewert type III (subcardial gastric carcinoma) refers to the esophagogastric junction and the distal esophagus are infiltrated from the bottom inward (located 2–5 cm below the GEJ) [4]. It has been agreed, clinically, that type I and III GEA can be staged and treated with reference to carcinoma of esophagus and gastric cancer, respectively, due to the similarity in pathology and biological behavior [5]. Although the latest TNM staging system (8th edition) classifies Siewert type II as esophageal cancer, it is difficult to determine whether the origin is gastric cancer or esophageal cancer, so the optimal treatment has been controversial.

At present, surgery is the basis for the treatment of Siewert type II GEA patients without distant metastasis, and the pivotal goal is to achieve radical resection. However, the treatment outcome of only surgery is often disappointing, which has prompted the development of multimodal therapy for GEA [6]. Neoadjuvant chemotherapy is superior to surgical treatment alone for resectable esophagus cancer and GEA in some randomized clinical trials [7,8] and has been widely used clinically. Currently, neoadjuvant chemotherapy for type II GEA is mainly aimed at patients with locally advanced tumors that invade the gastric wall to a depth of T3 or T4, and it is expected that surgical resection is difficult or cannot achieve R0 resection. Its main chemotherapy regimen mainly refers to the neoadjuvant chemotherapy regimen for gastric cancer [9]. In addition, neoadjuvant radiotherapy (nRT) is mainly used to control local disease and improve marginal negative resection. However, because of the contradictory results of some clinical trials [10–12], whether patients with GEA can benefit from nRT is still inconclusive and needs further study.

Moreover, the necessity of nRT for the treatment of cavity organ tumors is controversial and some studies have shown that nRT does not improve the survival of these patients [13]. In addition, radiotherapy may lead to edema, fibrosis, and normal tissue structure disorder in the surrounding tissues of the tumor, which makes it difficult for the surgeon to perform radical resection and increases the probability of postoperative complications [14,15]. Therefore, some researchers have proposed to exclude radiotherapy in the treatment of rectal cancer [14]. Does the idea of abandoning radiotherapy apply to all cavity organ tumors? Therefore, this
study aims to explore the significance of nRT for Siewert II tumor patients, so as to propose individualized treatment strategies.

This study tried to use the information from the specific cancer database, the Surveillance, Epidemiology, and End Results (SEER) database, and divided the treatment strategies into surgery-only cohort, nRT cohort, adjuvant radiotherapy (aRT) cohort, and surgery plus chemotherapy cohort to analyze the influence of nRT on the prognosis of non-metastatic Siewert II GEA patients.

**Methods**

**Data provenience**

The present study extracted GEA cases from the database through SEER Stat software. The SEER database incorporates basic demographic data and some clinical characteristics, mainly from 18 cancer registration centers, accounting for about 28% of the American populace [16]. This study is based on a retrospective analysis in the SEER database and has no identifiable patient information in the database, which is anonymous. Therefore, written informed consent is not required in this study. The study is based on the ethical standards of the Helsinki Declaration as well as national and international norms.

**Patient population**

GEA patients are derived from the up-to-date version of the SEER database with additional treatment fields (SEER 18, 1973–2014 varying), which was based on the November 2016 submission and was released in March 2018. Although there is no specific Siewert classification in this database, we classified cancers whose 'Primary Site' is 'C16.0-Cardia NOS' and 'CS v0204 + Schema' is 'EsophagusGEJunction' as Siewert type II GEA referring to previous studies [17,18]. We retrieved all Siewert type II GEA patients diagnosed pathologically between the years 2004–2015 from the SEER database. The extracted information mainly incorporated basic information (age, sex, race, insurance, and marital status), specific pathological data (tumor grade, pathological type, TNM stage), treatment information (operation, chemotherapy and radiotherapy), other clinical data (lymph node dissection, tumor size) and follow-up data. The database used the 7th (2010–2015) and 6th (2004–2015) TNM staging systems from 2004 to 2015, so we converted the 6th edition to the 7th edition based on CS Extension and CS Lymph Nodes. We selected patients with surgery code 30–80 from the SEER database, which means that these patients have received at least partial gastrectomy. This study only included patients with non-metastatic GEA (T1-4NxM0), and the specific process of inclusion and exclusion can be seen in Fig 1. Both neoadjuvant radiotherapy and adjuvant radiotherapy patients received chemotherapy after screening. We divided the treatment strategy into four cohorts: surgery cohort (patients only received surgery), surgery combined with chemotherapy cohort (patients underwent surgery and chemotherapy, without radiotherapy), and nRT cohort (patients treated with nRT and surgical treatment, with chemotherapy), aRT cohort (patients received surgical treatment combined with chemotherapy and aRT).

**Statistical analyses**

Overall survival (OS), that is, from the time of diagnosis of GEA to death or the last follow-up, was the principal end point of the study. First, the chi-square test was applied to compare patient characteristics between treatment groups. The log-rank test was utilized to estimate and analyze patients’ 3-year, 5-year, and median OS. We performed univariate and multivariate Cox models to analyze patients in each group and to determine risk ratios (HR) and 95%
This study uses propensity score matching to reduce the possibility of various treatment selection biases. Insurance, marital status, age, race, gender, pathological type, tumor grade, T stage, RNE and tumor size were used as matching criteria to estimate propensity scores in the T1-2N0M0 group. In addition to the above indicators, N stage was added as a matching criterion to estimate the propensity score in the T3N0M0/T1-3N+M0 and T4N0-3/xM0 group. Propensity score matching pairs were identified without replacement using a 1:1 nearest neighbor matching algorithm with caliper width determined by the recommendation from Austin (0.002 of the standard deviation of the logit of the PSs). All statistical analyses in this study were run under SPSS 26.0 software, and the inspection level of all statistical analyses was set to p-value less than 0.05. In addition, GraphPad Prism 8 software was used to draw the Kaplan-Meier (K-M) survival curve.

**Result**

**Basic characteristics of the patients**

Overall, after screening, 4,160 GEA patients were finally incorporated in this study. nRT was carried out in 24.57% (1,022) of the total population and around 12.19% (507) underwent aRT. About 45.70% (1,901) of patients received chemotherapy. The majority of the study group were married white, and 56.80% were older than 65. Most of the patients studied were in T1 stage, accounting for 42.54% (1,770), and 23.51% (978) were in T4 stage. Patients with tumor grades III and IV account for a high proportion (41.26%) of the population. The basic clinical and pathological features of the subjects were displayed in Table 1.
| Features | T1-2N0M0 (N = 2212) | T3N0M0/T1-3N+M0 (N = 970) | T4N0-3/xM0 (N = 978) |
|----------|---------------------|----------------------------|---------------------|
|          | Number (%)          | Number (%)                 | Number (%)          |
| Insurance Recode |                      |                            |                     |
| No/Unknown | 660 (29.84%)        | 221 (22.78%)               | 498 (50.92%)        |
| Insured   | 1552 (70.16%)       | 749 (77.22%)               | 480 (49.08%)        |
| Marital status |                   |                             |                     |
| Single/Unknown | 730 (33.00%)       | 317 (32.68%)               | 340 (34.76%)        |
| Married   | 1482 (67.00%)       | 633 (67.32%)               | 638 (65.24%)        |
| Race     |                      |                             |                     |
| Non-whites | 212 (9.58%)         | 103 (10.62%)               | 130 (13.29%)        |
| White     | 2000 (90.42%)       | 867 (89.38%)               | 848 (86.71%)        |
| Age <65 | 834 (37.70%)        | 429 (44.23%)               | 534 (54.60%)        |
| ≥65      | 1378 (62.30%)       | 541 (55.77%)               | 444 (45.40%)        |
| Sex       |                      |                             |                     |
| Female   | 510 (23.06%)        | 186 (19.18%)               | 218 (22.29%)        |
| Male     | 1702 (76.94%)       | 784 (80.82%)               | 760 (77.71%)        |
| Histology |                      |                             |                     |
| Adenocarcinomas | 2056 (92.95%)     | 809 (83.40%)               | 784 (80.16%)        |
| Cystic, mucinous and serous neoplasms | 156 (7.05%)       | 161 (16.60%)               | 194 (19.84%)        |
| Grade I | 310 (14.01%)        | 52 (5.36%)                 | 34 (3.48%)          |
| II       | 927 (41.91%)        | 325 (33.51%)               | 257 (26.28%)        |
| III/IV   | 636 (28.75%)        | 519 (53.51%)               | 636 (65.03%)        |
| Unknown  | 339 (15.33%)        | 74 (7.62%)                 | 51 (5.21%)          |
| T stage T1 | 1760 (79.57%)     | 10 (1.03%)                 | -                   |
| T2      | 452 (20.43%)        | 27 (2.78%)                 | -                   |
| T3      | -                   | 933 (96.19%)               | -                   |
| T4      | -                   | -                         | 978 (100%)          |
| N stage N0 | 2212 (100%)      | 746 (76.90%)               | 185 (18.92%)        |
| N1      | -                   | 104 (10.72%)               | 40 (4.09%)          |
| N2      | -                   | 70 (7.22%)                 | 13 (1.33%)          |
| N3      | -                   | 50 (5.16%)                 | 15 (1.53%)          |
| Unknown | -                   | -                         | 725 (74.13%)        |
| Therapy Surgery alone | 1721 (77.80%)  | 240 (24.74%)               | 235 (24.03%)        |
| Surgery + chemotherapy | 114 (5.15%)    | 139 (14.34%)               | 182 (18.61%)        |
| nRT      | 269 (12.17%)        | 473 (48.76%)               | 280 (28.63%)        |
| aRT      | 108 (4.88%)         | 118 (12.16%)               | 281 (28.73%)        |
| RNE      |                      |                            |                     |
| <15      | 1537 (69.48%)       | 513 (52.89%)               | 503 (51.43%)        |
| ≥15      | 638 (28.85%)        | 441 (45.46%)               | 456 (46.63%)        |
| Unknown  | 37 (1.67%)          | 16 (1.65%)                 | 19 (1.93%)          |
| Tumor size <3cm | 883 (39.92%)    | 82 (8.45%)                 | 29 (2.97%)          |
| ≥3cm and <5cm | 669 (30.24%)  | 441 (45.46%)               | 360 (36.81%)        |

(Continued)
Survival analysis before PSM

First, the results of Cox regression model analysis in the entire group showed that age, marital and insurance status, grade, pathological type, T stage, N stage, treatment mode, and regional lymph node examination (RNE) are closely related to OS (Table 2). The tumor outcomes of nRT, aRT, and surgery combined with chemotherapy were significantly better than surgery alone for patients with non-stage IV Siewert type II GEA (p = 0.004). The influences of various therapy modes on the prognosis of patients were further analyzed in subgroups of different stages. The K-M curve of OS in each stage was manifested in Fig 2.

About 12.16% of patients received nRT in the T1-2N0M0 subgroup. The efficacy of nRT is superior to that of aRT (HR 0.738, 95% CI 0.533–0.920; p = 0.048), and it is the same as that of surgery plus chemotherapy (HR 0.996, 95% CI 0.699–1.336; p = 0.836). Nonetheless, the overall survival of patients who only received surgery was indeed longer than that of nRT in patients with T1-2N0M0 stage (HR 0.674, 95% CI 0.539–0.842; p<0.001) (Fig 3A–3C). The median survival was 70, 46, 95, and 114 months for nRT, aRT, surgery combined with chemotherapy, and surgery alone cohorts, respectively (Table 3).

The nRT was administered to 48.76% of patients in the T3N0/T1-3N+M0 subgroup. The prognosis of patients undergoing nRT distinctly won upon that of patients undergoing surgical treatment alone (HR 0.765, 95% CI 0.621–0.943; p = 0.008), with median survival times of 48 and 39 months, respectively. There was no striking disparity in the survival between nRT and aRT cohort (HR 1.002, 95% CI 0.766–1.311; p = 0.989; Median survival: 51 months) or surgery combined with chemotherapy cohort (HR 1.183, 95% CI 0.898–1.559; p = 0.205; Median survival: 42 months) (Fig 3D–3F).

Only 28.63% of patients received nRT in the T4 subgroup, but the efficacy of nRT was markedly superior to that of surgery alone (HR 0.323, 95% CI 0.265–0.392; p<0.001), surgery combined with chemotherapy (HR 0.657, 95% CI 0.523–0.825; p<0.001), and aRT (HR 0.775, 95% CI 0.640–0.938; p = 0.008), with median survival of 31 months, 10 months, 20 months, and 26 months, respectively (Fig 3G–3I).

Survival analysis after PSM

The multiple 1:1 PSM to compare different treatment regimens created three new comparison subgroups in stage T1-2N0M0 patients: nRT versus surgery alone (n = 252 pairs), nRT versus surgery combined with chemotherapy (n = 114 pairs), and nRT versus aRT (n = 108 pairs). Further K-M analysis found there was no striking disparity between the OS of the nRT cohort and the surgery combined with the chemotherapy cohort (HR 1.096, 95% CI 0.764–1.573; p = 0.615), and the survival advantage compared with the aRT cohort disappeared (HR 1.228, 95% CI 0.866–1.742; p = 0.237), while the survival of the surgical treatment cohort was still significantly superior to the nRT cohort (HR 0.702, 95% CI 0.541–0.909; p = 0.005) (Fig 4A–4C).

The PSM analysis of stage T3N0M0/T1-3N+M0 patients, which contained 234 ones per matched group, indicated the OS of nRT was superior to surgery alone (HR 1.256, 95% CI 0.702, 95% CI 0.541–0.909; p = 0.005) (Fig 4A–4C).

Table 1. (Continued)

| Features | T1-2N0M0 (N = 2212) | T3N0M0/T1-3N+M0 (N = 970) | T4N0-3/xM0 (N = 978) |
|----------|---------------------|---------------------------|---------------------|
| Number (%) | Number (%) | Number (%) |
| ≥5cm | 120 (5.42%) | 301 (31.04%) | 431 (44.07%) |
| Unknown | 540 (24.42%) | 146 (15.05%) | 158 (16.15%) |

Abbreviations: GEA: Gastroesophageal junction adenocarcinoma; nRT: Neoadjuvant radiotherapy; aRT: Adjuvant radiotherapy; RNE: Regional nodes examined.

https://doi.org/10.1371/journal.pone.0251555.t001
Table 2. The Cox regression model analysis for OS of all Siewert type II GEA patients.

| Features                  | Univariate analysis | Multivariate analysis |
|---------------------------|---------------------|-----------------------|
|                           | P                   | HR        | 95%CI     | P          |
| Insurance status          | <0.001              |           |           | <0.001     |
| No/unknown                | Reference           | Reference   | Reference | Reference  |
| Insured                   | 0.848               | 0.775−0.929 | <0.001     |
| Marital status            | <0.001              |           |           | <0.001     |
| Single/Unknown            | Reference           | Reference   | Reference | Reference  |
| Married                   | 0.832               | 0.761−0.908 | <0.001     |
| Age, years                | <0.001              |           |           | <0.001     |
| <65                       | Reference           | Reference   | Reference | Reference  |
| ≥65                       | 1.773               | 1.619−1.941 | <0.001     |
| Race recode               | 0.068               |           |           |           |
| No-whites                 |                     |           |           |           |
| White                     | 0.373               |           |           |           |
| Female                    |                     |           |           |           |
| Male                      |                     |           |           |           |
| Histology                 | <0.001              |           |           | 0.038      |
| Adenocarcinomas           | Reference           | Reference   | Reference | Reference  |
| Cystic, mucinous and serous neoplasms | 1.134 | 1.007−1.278 | 0.038     |
| Grade                     | <0.001              |           |           | <0.001     |
| I                         | Reference           | Reference   | Reference | Reference  |
| II                        | 1.084               | 0.910−1.290 | 0.368     |
| III/IV                    | 1.425               | 1.197−1.696 | <0.001     |
| Unknown                   | 0.831               | 0.665−1.038 | 0.103     |
| T stage                   | <0.001              |           |           | <0.001     |
| T1                        | Reference           | Reference   | Reference | Reference  |
| T2                        | 1.590               | 1.360−1.859 | <0.001     |
| T3                        | 1.816               | 1.564−2.109 | <0.001     |
| T4                        | 2.260               | 1.869−2.733 | <0.001     |
| N stage                   | <0.001              |           |           | <0.001     |
| N0                        | Reference           | Reference   | Reference | Reference  |
| N1                        | 1.550               | 1.234−1.946 | <0.001     |
| N2                        | 1.914               | 1.427−2.567 | <0.001     |
| N3                        | 2.892               | 2.160−3.870 | <0.001     |
| Unknown                   | 1.712               | 1.439−2.037 | <0.001     |
| Treatment methods         | <0.001              |           |           | 0.004      |
| Surgery alone             | Reference           | Reference   | Reference | Reference  |
| Surgery plus chemotherapy | 0.898               | 0.757−0.961 | 0.046     |
| nRT                       | 0.838               | 0.739−0.949 | 0.005     |
| aRT                       | 0.824               | 0.714−0.950 | 0.008     |
| RNE                       | 0.042               |           |           | <0.001     |
| <15                       | Reference           | Reference   | Reference | Reference  |
| ≥15                       | 0.703               | 0.641−0.771 | <0.001     |
| Unknown                   | 0.865               | 0.614−1.217 | 0.405     |
| Tumor size                | <0.001              |           |           | 0.126      |
| <3cm                      | Reference           | Reference   | Reference | Reference  |
| ≥3cm and <5cm             | 1.089               | 0.950−1.247 | 0.220     |

(Continued)
In addition, nRT has no obvious survival superiority compared with aRT (HR 0.966, 95% CI 0.685–1.362; p = 0.840) after matching (n = 107 pairs). Similarly, no significant disparities in OS could be identified between the nRT and the surgery combined with chemotherapy groups (HR 1.133, 95% CI 0.813–1.580; p = 0.447) after PSM analysis (n = 124 pairs) (Fig 4D–4F).

The 1:1 PSM analysis among stage T4 patients, in which 96 patients treated with nRT were matched to 96 patients undergoing surgery alone, yielded OS favored the nRT cohort (HR 0.523, 95% CI 0.378–0.721; p < 0.001). Versus the surgery plus chemotherapy group, the nRT group manifested a distinctly longer survival (HR 0.769, 95% CI 0.596–0.993; p = 0.033) after PSM analysis (n = 152 pairs). And matched patients with nRT, after matching (n = 249 pairs), were related to a significantly better OS than the aRT cohort (HR 0.752, 95% CI 0.597 to 0.942; p = 0.045) (Fig 4G–4I). The characteristics of patients before and after PSM in each group are shown in S1–S9 Tables.

Discussion

Surgical resection, as the main treatment for most operable GEA patients, has always been associated with poor survival, which may be due to the relative difficulty of some patients to achieve radical resection or some patients still have distant metastases after radical resection [19]. For this reason, the neoadjuvant therapy has become to be the most shining star in the field of clinical treatment of GEA, including preoperative chemotherapy and radiotherapy. Existing studies have confirmed that neoadjuvant chemotherapy is superior to surgery alone and is a comprehensive treatment method that is easily accepted by GEA patients [20,21]. Although some randomized trials have been conducted so far, the treatment of nRT in GEA patients remains controversial. The CROSS trial is a multiagency phase III clinical trial in which 366 ones with esophageal cancer or GEA were randomly allotted to the surgical-only, preoperative or postoperative chemoradiotherapy groups, confirming that preoperative chemoradiotherapy is superior to surgical treatment alone and that preoperative treatment is the standard treatment [22]. However, the results of a comparative study showed that preoperative radiotherapy did not significantly improve the OS of the lower esophagus and GEA [23]. What’s more, another large retrospective analysis showed that nRT seems to enhance the venture of death among patients with resectable GEA [24].

Hence, we believe that non-metastatic GEA patients should be further staged to discuss the effect of nRT, rather than considered as a whole. First of all, although radical surgical resection and adjuvant treatment provide the possibility of curing localized diseases, most patients with clinical T3 and T4 tumors have a poor prognosis, especially T4 stage [25]. What’s more, if patients with esophageal cancer have lymph node metastasis, the prognosis is generally frustrating, and adjuvant therapy is recommended [26]. In addition, whether induction therapy

Table 2. (Continued)

| Features | classification | Univariate analysis | HR | 95%CI | P    |
|----------|---------------|---------------------|----|------|------|
| ≥5cm     |               | 1.196               | 1.024–1.397 | 0.024 |
| Unknown  |               | 1.127               | 0.973–1.305 | 0.112 |

Abbreviations GEA: Gastroesophageal junction adenocarcinoma; nRT: Neoadjuvant radiotherapy; aRT: Adjuvant radiotherapy; RNE: Regional nodes examined; OS: Overall survival; HR: Hazard ratio; CI: Confidence interval.

https://doi.org/10.1371/journal.pone.0251555.t002
can improve the survival of patients with early localized disease (T1-2N0M0) is now a fierce controversy [27,28]. With these questions in mind, GEA patients were separated into three subgroups: T1-2N0M0, T3N0/T1-3N+M0, and T4NxM0 to analyze the influence of various therapy options including nRT on the prognosis.
For all we know, our study is the only study to evaluate the impact of nRT on the prognosis of non-metastatic GEA in different stages. Firstly, the results revealed that nRT was detrimental to prolonged survival in T1-2N0M0 patients. Not only for GEA but also for pancreatic cancer, the question whether neoadjuvant therapy should be used in early-stage patients has always been a question. The reason for opposing neoadjuvant therapy for patients with early resectable cancer is that neoadjuvant therapy may cause patients to miss the best opportunity for surgery, making lesions that could be resectable at R0 progress to incurable resection, or even distant metastases [29,30]. Our consequences are confirmed by other retrospective researches, indicating that routine use of neoadjuvant induction therapy may be adverse rather than beneficial to survival in all T1-2N0M0 patients [31]. The real challenge for stage T1-2 esophageal or GEA remains to perfect the precision of the inspection of microscopic lymph node metastases, but currently imaging and endoscopy methods seem to be inadequate [31]. In addition, the T1-2N0M0 stage esophageal cancer or GEA is a localized disease in which the tumor infiltrates into the submucosal layer and may increase the risk of lymph node metastasis, but removal of tumor lesions and local lymph node dissection may be adequate to bring the disease under control, and additional neoadjuvant or adjuvant therapy may have no

Fig 3. The K-M curves for OS in non-metastatic Siewert type II EGA patients at different stages before PSM. A. Surgery only vs Neoadjuvant radiotherapy in T1-2N0M0; B. Surgery combined with chemotherapy vs Neoadjuvant radiotherapy in T1-2N0M0; C. Neoadjuvant radiotherapy vs Adjuvant radiotherapy in T1-2N0M0; D. Surgery only vs Neoadjuvant radiotherapy in T3N0/T1-3N+M0; E. Surgery combined with chemotherapy vs Neoadjuvant radiotherapy in T3N0/T1-3N+M0; F. Neoadjuvant radiotherapy vs Adjuvant radiotherapy in T3N0/T1-3N+M0; G. Surgery only vs Neoadjuvant radiotherapy in T4; H. Surgery combined with chemotherapy vs Neoadjuvant radiotherapy in T4; I. Neoadjuvant radiotherapy vs Adjuvant radiotherapy in T4.

https://doi.org/10.1371/journal.pone.0251555.g003
prognostic benefit [32]. Therefore, combined with our results, only surgery is advised as the main therapy for patients with stage T1–2N0M0 GEA.

The results of a European multicenter retrospective study, which collected data from 30 European centers of patients undergoing esophageal/GEA surgery, suggest a remarkable survival advantage from nRT for T3N0M0 carcinoma of esophagus [33]. This also further confirms our findings that T3N0M0 should be considered as a locally advanced esophageal cancer like T1–3N+M0, which can benefit from neoadjuvant therapy, but the risk of postoperative complications will not increase significantly. The nRT, aRT, and surgery combined with chemotherapy all can prominently improve OS compared to only surgery for the large subgroup of T3N0/T1–3N+M0 patients, but the best treatment plan still needs further study. In addition, a review also has yielded similar results, showing that multimodal treatment combined with surgery, radiotherapy, and neoadjuvant therapy can improve the prognosis of most locally advanced operable esophageal and gastric adenocarcinomas, but there are still some controversies about the best treatment [34].

We observed that nRT improved the OS of T3N0M0/T1–3N+M0 and T4 stage GEA patients. Especially for T4 patients, nRT has a significantly better impact on survival than aRT and surgery combined with chemotherapy. Most of the GEA patients with stage T4 invade adjacent structures (such as lung, large blood vessels, and trachea), and the prognosis is greatly dismal. Although modern surgical techniques have been significantly improved, these tumors are generally regarded as not directly surgically treated, which has also led to the increasingly prominent role of neoadjuvant therapy [35]. It is clear that patients with R0 resection have a longer survival period than R1 or R2 resection [36]. The nRT can transform unresectable or even inoperable tumors into resectable lesions, which cannot be achieved by postoperative adjuvant therapy. Analyses have shown that the median overall resection rate of T4 disease is 59% (35%–78%), and the R0 resection rate is 36.5% (32%–44%); this effect is mainly due to the role of neoadjuvant chemoradiotherapy [37]. Such achievement should enable patients with T4 stage esophagus or GEA without metastasis to be completely cured after R0 resection, thereby prolonging survival [38]. Therefore, a combination of nRT is likely the best choice.

Table 3. Multivariate Cox analysis of OS with various treatment methods, median survival and 3-year and 5-year OS.

| TNM Stage    | Treatments       | Multivariate HR (95% CI) | P value | Median survival | 3-year OS    | 5-year OS   |
|--------------|------------------|--------------------------|---------|-----------------|--------------|-------------|
| T1–2N0M0     | Only surgery     | Reference                | <0.001  | 114             | 77.91%       | 66.94%      |
|              | Surgery +化疗    | 1.499 (1.121–2.004)      | 0.006   | 95              | 64.82%       | 54.57%      |
|              | nRT              | 1.465 (1.195–1.795)      | <0.001  | 70              | 64.62%       | 50.81%      |
|              | aRT              | 1.829 (1.402–2.386)      | <0.001  | 46              | 57.83%       | 43.54%      |
| T3N0/T1–3N+M0| Only surgery     | Reference                | 0.008   | 39              | 40.81%       | 27.39%      |
|              | Surgery +化疗    | 0.803 (0.503–0.968)      | 0.041   | 42              | 54.66%       | 40.03%      |
|              | nRT              | 0.755 (0.612–0.932)      | 0.009   | 48              | 56.94%       | 42.61%      |
|              | aRT              | 0.716 (0.534–0.958)      | 0.025   | 51              | 58.06%       | 43.59%      |
| T4N0–3/xM0   | Only surgery     | Reference                | <0.001  | 10              | 17.06%       | 9.74%       |
|              | Surgery +化疗    | 0.594 (0.476–0.740)      | <0.001  | 20              | 30.16%       | 21.29%      |
|              | nRT              | 0.347 (0.263–0.449)      | <0.001  | 31              | 45.80%       | 37.08%      |
|              | aRT              | 0.584 (0.498–0.689)      | <0.001  | 26              | 38.59%       | 24.35%      |

Abbreviations OS: Overall survival; HR: Hazard ratio; CI: Confidence interval; nRT: Neoadjuvant radiotherapy; aRT: Adjuvant radiotherapy.

https://doi.org/10.1371/journal.pone.0251555.t003
when deciding the optimal scheme for treating patients with T4 GEA. Yet, the use of nRT in T4 patients is not ideal (only 28.63%) according to data extracted from the SEER database. Hence, the clinical importance of nRT for T4 GEA patients cannot be overemphasized.

Although we have extracted a large number of patient data with follow-up information from the SEER database, some of the inherent limitations of the database are related to the current research. However, as a national database, the SEER database does not provide information about the specific plan, dose, and duration of radiotherapy and chemotherapy. We can only determine whether the patient receives radiotherapy or chemotherapy and the sequence of radiotherapy and surgery. Among them, the information of radiation dose is particularly important. For example, a crossover test has shown that preoperative radiotherapy has survival benefits for GEA patients, but the dose of radiotherapy used is much lower than the dose often used in conventional neoadjuvant radiotherapy. Toxic and side effects caused by radiotherapy are an important issue that cannot be ignored in clinical practice. As the radiation dose increases, the toxicity may further increase. Different medical institutions in the United States have different radiation doses and techniques used in preoperative radiotherapy, which is a difference that cannot be balanced by the use of PSM in this study.
Another shortcoming is that there is no information on the patient’s tumor regression after radiotherapy, which has a great impact on the patient’s follow-up treatment and long-term survival. The SEER database, despite this limitation, is still a valuable database for studying cancer treatment. In addition, this study, as a retrospective analysis, perform propensity score matching to reduce some defects such as selection bias, but the conclusions should be ulteriorly proved by randomized controlled trials.

Conclusions
In these carefully selected patients, the present study made the following recommendations: nRT can improve the prognosis of patients with T3N0M0/T1-3N+M0 and T4 Siewert type II GEA, and it seems to be a better treatment for T4 patients. Surgery alone seems to be sufficient, and nRT is not conducive to prolonging the survival of Siewert II GEA patients with T1-2N0M0 stage. Of course, further prospective trials are needed to verify this conclusion.

Supporting information
S1 Table. Features of stage T1-2N0M0 patients in the surgery only group and the neoadjuvant radiotherapy group before and after PSM.
(DOCX)
S2 Table. Features of stage T1-2N0M0 patients in the surgery plus chemotherapy group and the neoadjuvant radiotherapy group before and after PSM.
(DOCX)
S3 Table. Features of stage T1-2N0M0 patients in the adjuvant radiotherapy group and the neoadjuvant radiotherapy group before and after PSM.
(DOCX)
S4 Table. Features of stage T3N0M0/T1-3N+M0 patients in the surgery only group and the neoadjuvant radiotherapy group before and after PSM.
(DOCX)
S5 Table. Features of stage T3N0M0/T1-3N+M0 patients in the surgery plus chemotherapy group and the neoadjuvant radiotherapy group before and after PSM.
(DOCX)
S6 Table. Features of stage T3N0M0/T1-3N+M0 patients in the adjuvant radiotherapy group and the neoadjuvant radiotherapy group before and after PSM.
(DOCX)
S7 Table. Features of stage T4 patients in the surgery only group and the neoadjuvant radiotherapy group before and after PSM.
(DOCX)
S8 Table. Features of stage T4 patients in the surgery plus chemotherapy group and the neoadjuvant radiotherapy group before and after PSM.
(DOCX)
S9 Table. Features of stage T4 patients in the adjuvant radiotherapy group and the neoadjuvant radiotherapy group before and after PSM.
(DOCX)
Acknowledgements
We are grateful to the SEER database for providing these data in this study.

Author Contributions
Conceptualization: Yuan Zhou, Dan Wang.
Data curation: MengXiang Tian, Cenap Güngör, Dan Wang.
Formal analysis: Dan Wang.
Investigation: Dan Wang.
Methodology: MengXiang Tian, Dan Wang.
Project administration: Dan Wang.
Resources: Dan Wang.
Software: MengXiang Tian, Dan Wang.
Validation: Yuan Zhou.
Visualization: MengXiang Tian.
Writing – original draft: Yuan Zhou, MengXiang Tian, Dan Wang.
Writing – review & editing: Yuan Zhou, Cenap Güngör, Dan Wang.

References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7–30. http://doi.org/10.3322/caac.21590. PMID: 31912902
2. Buas MF, Vaughan TL. Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. Semin Radiat Oncol. 2013; 23(1):3–9. http://doi.org/10.1016/j.semradonc.2012.09.008. PMID: 23207041
3. Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013; 381(9864):400–12. http://doi.org/10.1016/S0140-6736(12)60643-6 PMID: 23207041
4. Rudiger SJ, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg. 2000; 232(3):353–61. http://doi.org/10.1097/00000658-200009000-00007. PMID: 10973385
5. Zhu K, Xu Y, Fu J, Mohamud FA, Duan Z, Tan S, et al. Proximal Gastrectomy versus Total Gastrectomy for Siewert Type II Adenocarcinoma of the Esophagogastric Junction: A Comprehensive Analysis of Data from the SEER Registry. Dis Markers. 2019; 2019:9637972. http://doi.org/10.1155/2019/9637972. PMID: 31976023
6. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355(1):11–20. http://doi.org/10.1056/NEJMoa055531. PMID: 16822992
7. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011; 12(7):681–92. http://doi.org/10.1016/S1470-2045(11)70142-5 PMID: 21684205
8. Kidane B, Coughlin S, Vogt K, Malthaner R. Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst Rev. 2015(5):D1556. http://doi.org/10.1002/14651858.CD001556.pub3. PMID: 25988291
9. Lutz MP, Zalcberg JR, Ducrœx M, Adenis A, Allum W, Aust D, et al. The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma. Eur J Cancer. 2019; 112:1–8. http://doi.org/10.1016/j.ejca.2019.01.106. PMID: 30878666
10. Deng HY, Wang WP, Wang YC, Hu WP, Ni PZ, Lin YD, et al. Neoadjuvant chemoradiotherapy or chemotherapy? A comprehensive systematic review and meta-analysis of the options for neoadjuvant...
therapy for treating oesophageal cancer. Eur J Cardiothorac Surg. 2017; 51(3):421–31. http://doi.org/10.1093/ejcts/ezw315. PMID: 27694253

11. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011; 12(7):681–92. http://doi.org/10.1016/S1470-2045(11)70142-5. PMID: 21684205

12. Altorki N, Harrison S. What is the role of neoadjuvant chemotherapy, radiation, and adjuvant treatment in resectable esophageal cancer? Ann Cardiothorac Surg. 2017; 6(2):167–74. http://doi.org/10.21037/acs.2017.03.16. PMID: 28447006

13. Scalfani F, Cunningham D. Neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer. Future Oncol. 2014; 10(14):2243–57. http://doi.org/10.2217/fon.14.127. PMID: 25471037

14. Hu MH, Huang RK, Zhao RS, Yang KL, Wang H. Does neoadjuvant therapy increase the incidence of anastomotic leakage after anterior resection for mid and low rectal cancer? A systematic review and meta-analysis. Colorectal Dis. 2017; 19(1):16–26. http://doi.org/10.1111/codi.13424. PMID: 27321374

15. Geisler D, Marks J, Marks G. Laparoscopic colorectal surgery in the irradiated pelvis. Am J Surg. 2004; 188(3):267–70. http://doi.org/10.1016/j.amjsurg.2004.04.007. PMID: 15450832

16. Engels EA, Pfeiffer RM, Ricker W, Wheeler W, Parsons R, Warren J. Use of surveillance, epidemiology, and end results-medicare data to conduct case-control studies of cancer among the US elderly. Am J Epidemiol. 2011; 174(7):860–70. http://doi.org/10.1093/aje/kwr146. PMID: 21821540

17. Miccio JA, Oladeru OT, Yang J, Xue Y, Choi M, Zhang Y, et al. Neoadjuvant vs. adjuvant treatment of Siewert type II gastroesophageal junction cancer: an analysis of data from the surveillance, epidemiology, and end results (SEER) registry. J Gastrointest Oncol. 2016; 7(3):403–10. http://doi.org/10.21037/jgo.2015.10.06. PMID: 27284473

18. Zhu K, Xu Y, Fu J, Mohamud FA, Duan Z, Tan S, et al. Proximal Gastrectomy versus Total Gastrectomy for Siewert Type II Adenocarcinoma of the Esophagogastric Junction: A Comprehensive Analysis of Data from the SEER Registry. Dis Markers. 2019; 2019:9637972. http://doi.org/10.1155/2019/9637972. PMID: 31976023

19. Buas MF, Vaughan TL. Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. Semin Radiat Oncol. 2013; 23(1):3–9. http://doi.org/10.1016/j.semradonc.2012.09.006. PMID: 23207041

20. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355(1):11–20. http://doi.org/10.1056/NEJMoa055531. PMID: 16822992

21. Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011; 29(13):1715–21. http://doi.org/10.1200/JCO.2010.33.0597. PMID: 21448466

22. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge HM, Wijnhoven BP. et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012; 366(22):2074–84. http://doi.org/10.1056/NEJMoa1112088. PMID: 22646630

23. Zafar SN, Blum M, Chiang YJ, Ajani JA, Estrella JS, Das P, et al. Preoperative Chemoradiation Versus Chemotherapy in Gastroesophageal Junction Adenocarcinoma. Ann Thorac Surg. 2020; 110(2):398–405. http://doi.org/10.1016/j.athoracsur.2020.03.024. PMID: 32289300

24. Tian S, Jiang R, Madden NA, Ferris MJ, Buchwald ZS, Xu KM, et al. Survival outcomes in patients with gastric and gastroesophageal junction adenocarcinomas treated with perioperative chemotherapy with or without preoperative radiotherapy. Cancer-Am Cancer Soc. 2020; 126(1):37–45. http://doi.org/10.1002/cncr.32516. PMID: 31532544

25. Liu D, Lu M, Li J, Yang Z, Feng Q, Zhou M, et al. The patterns and timing of recurrence after curative resection for gastric cancer in China. World J Surg Oncol. 2016; 14(1):305. http://doi.org/10.1186/s12957-015-0479-9. PMID: 27293121

26. Han J, Zhu W, Yu C, Zhou X, Li T, Zhang X. Clinical study of concurrent chemoradiotherapy or radiotherapy alone for esophageal cancer patients with positive lymph node metastasis. Tumori. 2012; 98(1):60–5. http://doi.org/10.1700/1063.11501. PMID: 22485703

27. Semenkovich TR, Panni RZ, Hudson JL, Thomas T, Elmore LC, Chang SH, et al. Comparative effectiveness of upfront esophagectomy versus induction chemoradiation in clinical stage T2N0 esophageal cancer: A decision analysis. J Thorac Cardiovasc Surg. 2018; 155(5):2221–30. http://doi.org/10.1016/j.jtcs.2018.01.006. PMID: 29287000

28. Speicher PJ, Ganapathi AM, Englum BR, Hartwig MG, Onaitis MW, D’Amico TA, et al. Induction therapy does not improve survival for clinical stage T2N0 esophageal cancer. J Thorac Oncol. 2014; 9(8):1195–201. http://doi.org/10.1097/JTO.0000000000000226. PMID: 25157773
29. Lanuti M. Early-stage (cT2N0) esophageal cancer: Should induction therapy be a standard? J Thorac Cardiovasc Surg. 2018; 155(5):2231–2. http://doi.org/10.1016/j.jtcvs.2018.02.029. PMID: 29525256

30. Wang D, Liu C, Zhou Y, Yan T, Li C, Yang Q, et al. Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis. Radiat Oncol. 2020; 15(1):107. http://doi.org/10.1186/s13014-020-01561-z. PMID: 32404114

31. Crabtree TD, Kosinski AS, Puri V, Burfeind W, Bharat A, Patterson GA, et al. Evaluation of the reliability of clinical staging of T2 N0 esophageal cancer: a review of the Society of Thoracic Surgeons database. Ann Thorac Surg. 2013; 96(2):382–90. http://doi.org/10.1016/j.athoracsur.2013.03.093. PMID: 23731608

32. Markar SR, Gronnier C, Pasquer A, Duhamel A, Beal H, Thereaux J, et al. Role of neoadjuvant treatment in clinical T2N0M0 oesophageal cancer: results from a retrospective multi-center European study. Eur J Cancer. 2016; 56:59–68. http://doi.org/10.1016/j.ejca.2015.11.024. PMID: 26808298

33. Mantziari S, Gronnier C, Renaud F, Duhamel A, Thereaux J, Brigand C, et al. Survival Benefit of Neoadjuvant Treatment in Clinical T3N0M0 Esophageal Cancer: Results From a Retrospective Multicenter European Study. Ann Surg. 2017; 266(5):805–13. http://doi.org/10.1097/SLA.0000000000002402. PMID: 28742698

34. Davidson M, Chau I. Multimodality treatment of operable gastric and oesophageal adenocarcinoma: evaluating neoadjuvant, adjuvant and perioperative approaches. Expert Rev Anticancer Ther. 2018; 18(4):327–38. http://doi.org/10.1080/14737140.2018.1438271. PMID: 29431018

35. Gamliel Z, Krasna MJ. Multimodality treatment of esophageal cancer. Surg Clin North Am. 2005; 85(3):621–30. http://doi.org/10.1016/j.suc.2005.01.011. PMID: 15927656

36. Matsubara T, Ueda M, Kokudo N, Takahashi T, Muto T, Yanagisawa A. Role of esophagectomy in treatment of esophageal carcinoma with clinical evidence of adjacent organ invasion. World J Surg. 2001; 25(3):279–84. http://doi.org/10.1007/s0026800020060. PMID: 11343176

37. Seto Y, Chin K, Gomi K, Kozuka T, Fukuda T, Yamada K, et al. Treatment of thoracic esophageal carcinoma invading adjacent structures. Cancer Sci. 2007; 98(7):937–42. http://doi.org/10.1111/j.1349-7006.2007.00479.x. PMID: 17441965

38. Makino T, Doki Y. Treatment of T4 esophageal cancer. Definitive chemo-radiotherapy vs chemo-radiotherapy followed by surgery. Ann Thorac Cardiovasc Surg. 2011; 17(3):221–8. http://doi.org/10.5761/atcs.ra.11.01676. PMID: 21697781